{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:59:54Z","timestamp":1794013194513,"version":"4.8.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Invest Radiol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The aim of this report was to characterize the key physicochemical, pharmacokinetic (PK), and magnetic resonance imaging (MRI) properties of gadoquatrane (BAY 1747846), a newly designed tetrameric, macrocyclic, extracellular gadolinium-based contrast agent (GBCA) with high relaxivity and stability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>The r1-relaxivities of the tetrameric gadoquatrane at 1.41 and 3.0 T were determined in human plasma and the nuclear magnetic relaxation dispersion profiles in water and plasma. The complex stability was analyzed in human serum over 21 days at pH 7.4 at 37\u00b0C and was compared with the linear GBCA gadodiamide and the macrocyclic GBCA (mGBCA) gadobutrol. In addition, zinc transmetallation assay was performed to investigate the kinetic inertness. Protein binding and the blood-to-plasma ratio were determined in vitro using rat and human plasma. The PK profile was evaluated in rats (up to 7 days postinjection). Magnetic resonance imaging properties were investigated using a glioblastoma (GS9L) rat model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The new chemical entity gadoquatrane is a macrocyclic tetrameric Gd complex with one inner sphere water molecule per Gd (<jats:italic toggle=\"yes\">q<\/jats:italic> = 1). Gadoquatrane showed high solubility in buffer (1.43 mol Gd\/L, 10 mM Tris-HCl, pH 7.4), high hydrophilicity (logP \u22124.32 in 1-butanol\/water), and negligible protein binding. The r1-relaxivity of gadoquatrane in human plasma per Gd of 11.8 mM<jats:sup>\u22121<\/jats:sup>\u00b7s<jats:sup>\u22121<\/jats:sup> (corresponding to 47.2 mM<jats:sup>\u22121<\/jats:sup>\u00b7s<jats:sup>\u22121<\/jats:sup> per molecule at 1.41 T at 37\u00b0C, pH 7.4) was more than 2-fold (8-fold per molecule) higher compared with established mGBCAs. Nuclear magnetic relaxation dispersion profiles confirmed the more than 2-fold higher r1-relaxivity in human plasma for the clinically relevant magnetic field strengths from 0.47 to 3.0 T. The complex stability of gadoquatrane at physiological conditions was very high. The observed Gd release after 21 days at 37\u00b0C in human serum was below the lower limit of quantification. Gadoquatrane showed no Gd<jats:sup>3+<\/jats:sup> release in the presence of zinc in the transmetallation assay. The PK profile (plasma elimination, biodistribution, recovery) was comparable to that of gadobutrol. In MRI, the quantitative evaluation of the tumor-to-brain contrast in the rat glioblastoma model showed significantly improved contrast enhancement using gadoquatrane compared with gadobutrol at the same Gd dose administered (0.1 mmol Gd\/kg body weight). In comparison to gadoterate meglumine, similar contrast enhancement was reached with gadoquatrane with 75% less Gd dose. In terms of the molecule dose, this was reduced by 90% when compared with gadoterate meglumine. Because of its tetrameric structure and hence lower number of molecules per volume, all prepared formulations of gadoquatrane were iso-osmolar to blood.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The tetrameric gadoquatrane is a novel, highly effective mGBCA for use in MRI. Gadoquatrane provides favorable physicochemical properties (high relaxivity and stability, negligible protein binding) while showing essentially the same PK profile (fast extracellular distribution, fast elimination via the kidneys in an unchanged form) to established mGBCAs on the market. Overall, gadoquatrane is an excellent candidate for further clinical development.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rli.0000000000000889","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T06:11:09Z","timestamp":1655273469000},"page":"629-638","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":65,"title":["Preclinical Profile of Gadoquatrane"],"prefix":"10.1097","volume":"57","author":[{"given":"Jessica","family":"Lohrke","sequence":"first","affiliation":[{"name":"MR & CT Contrast Media Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Berger","sequence":"additional","affiliation":[{"name":"Synthetic Modalities"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Frenzel","sequence":"additional","affiliation":[{"name":"MR & CT Contrast Media Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph-Stephan","family":"Hilger","sequence":"additional","affiliation":[{"name":"Synthetic Modalities"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Jost","sequence":"additional","affiliation":[{"name":"MR & CT Contrast Media Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Panknin","sequence":"additional","affiliation":[{"name":"Synthetic Modalities"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Bauser","sequence":"additional","affiliation":[{"name":"Synthetic Modalities"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Ebert","sequence":"additional","affiliation":[{"name":"Program Management and Operations, Pharmaceuticals, Bayer AG, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubertus","family":"Pietsch","sequence":"additional","affiliation":[{"name":"MR & CT Contrast Media Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"key":"bib1-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-015-0275-4","article-title":"25 years of contrast-enhanced MRI: developments, current challenges and future perspectives","volume":"33","year":"2016","journal-title":"Adv Ther"},{"key":"bib2-20250802","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1021\/cr980440x","article-title":"Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications","volume":"99","year":"1999","journal-title":"Chem Rev"},{"key":"bib3-20250802","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1007\/s00330-008-0977-y","article-title":"Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions","volume":"18","year":"2008","journal-title":"Eur Radiol"},{"key":"bib4-20250802","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/RLI.0b013e3181852171","article-title":"Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C","volume":"43","year":"2008","journal-title":"Invest Radiol"},{"key":"bib5-20250802","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium\u2014a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"bib6-20250802","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.rli.0000253505.88945.d5","article-title":"Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (OmniScan)","volume":"42","year":"2007","journal-title":"Invest Radiol"},{"key":"bib7-20250802","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/17111243","article-title":"Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?","volume":"80","year":"2007","journal-title":"Br J Radiol"},{"key":"bib8-20250802","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1148\/radiol.13131669","article-title":"High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material","volume":"270","year":"2014","journal-title":"Radiology"},{"key":"bib9-20250802","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","article-title":"Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation","volume":"49","year":"2014","journal-title":"Invest Radiol"},{"key":"bib10-20250802","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/10408444.2019.1592109","article-title":"Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents","volume":"49","year":"2019","journal-title":"Crit Rev Toxicol"},{"key":"bib11-20250802","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1148\/radiol.15150025","article-title":"Intracranial gadolinium deposition after contrast-enhanced MR imaging","volume":"275","year":"2015","journal-title":"Radiology"},{"issue":"suppl 2","key":"bib12-20250802","first-page":"1","article-title":"Gadolinium contrast agents\u2014are they really safe?","volume":"18","year":"2017","journal-title":"J Vasc Access"},{"key":"bib13-20250802","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11547-015-0614-1","article-title":"Gadolinium-based contrast agents: did we miss something in the last 25 years?","volume":"121","year":"2016","journal-title":"Radiol Med"},{"key":"bib14-20250802","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1148\/radiol.2015150805","article-title":"Residual or retained gadolinium: practical implications for radiologists and our patients","volume":"275","year":"2015","journal-title":"Radiology"},{"key":"bib15-20250802","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/RLI.0000000000000454","article-title":"Advocating the development of next-generation high-relaxivity gadolinium chelates for clinical magnetic resonance","volume":"53","year":"2018","journal-title":"Invest Radiol"},{"key":"bib16-20250802","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1021\/ja00381a009","article-title":"Model-free approach to the interpretation of nuclear magnetic resonance relaxation in macromolecules. 1. Theory and range of validity","volume":"104","year":"1982","journal-title":"J Am Chem Soc"},{"key":"bib17-20250802","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/jps.10332","article-title":"Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding","volume":"92","year":"2003","journal-title":"J Pharm Sci"},{"key":"bib18-20250802","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cbi.2007.01.001","article-title":"Human hepatocytes: isolation, cryopreservation and applications in drug development","volume":"168","year":"2007","journal-title":"Chem Biol Interact"},{"key":"bib19-20250802","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/DMR-100100564","article-title":"Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction","volume":"32","year":"2000","journal-title":"Drug Metab Rev"},{"key":"bib20-20250802","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00234-019-02256-3","article-title":"Impact of brain tumors and radiotherapy on the presence of gadolinium in the brain after repeated administration of gadolinium-based contrast agents: an experimental study in rats","volume":"61","year":"2019","journal-title":"Neuroradiology"},{"key":"bib21-20250802","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/RLI.0000000000000563","article-title":"Physicochemical and pharmacokinetic profiles of gadopiclenol A new macrocyclic gadolinium chelate with high T1 relaxivity","volume":"54","year":"2019","journal-title":"Invest Radiol"},{"key":"bib22-20250802","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/RLI.0000000000000572","article-title":"Evaluation of gadopiclenol and P846, 2 high-relaxivity macrocyclic magnetic resonance contrast agents without protein binding, in a rodent model of hepatic metastases potential solutions for improved enhancement at ultrahigh field strength","volume":"54","year":"2019","journal-title":"Invest Radiol"},{"key":"bib23-20250802","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/RLI.0000000000000577","article-title":"Comparison of the relaxivities of macrocyclic gadolinium-based contrast agents in human plasma at 1.5, 3, and 7 T, and blood at 3 T","volume":"54","year":"2019","journal-title":"Invest Radiol"},{"key":"bib24-20250802","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10534-008-9135-x","article-title":"Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review","volume":"21","year":"2008","journal-title":"Biometals"},{"key":"bib25-20250802","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1039\/b510982p","article-title":"Strategies for increasing the sensitivity of gadolinium based MRI contrast agents","volume":"35","year":"2006","journal-title":"Chem Soc Rev"},{"key":"bib26-20250802","first-page":"25","article-title":"Relaxivity of gadolinium(III) complexes: theory and mechanism","year":"2013","journal-title":"Merbach A, Helm L, T\u00f3th \u00c9, eds. The chemistry of contrast agents in medical magnetic resonance imaging. 2nd ed. Magn Reson Imaging"},{"key":"bib27-20250802","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4155\/fmc.09.174","article-title":"Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications","volume":"2","year":"2010","journal-title":"Future Med Chem"},{"key":"bib28-20250802","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/RLI.0b013e3181ee6a49","article-title":"High-relaxivity magnetic resonance imaging contrast agents. Part 2. Optimization of inner- and second-sphere relaxivity","volume":"45","year":"2010","journal-title":"Invest Radiol"},{"key":"bib29-20250802","first-page":"157","article-title":"Stability and toxicity of contrast agents","year":"2013","journal-title":"Merbach A, Helm L, Toth E, eds. The chemistry of Contrast Agents in Medical Magnetic Resonance Imaging"},{"key":"bib30-20250802","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1021\/acs.chemrev.8b00363","article-title":"Chemistry of MRI contrast agents: current challenges and new Frontiers","volume":"119","year":"2019","journal-title":"Chem Rev"},{"key":"bib31-20250802","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1002\/(SICI)1097-458X(199806)36:13<S200::AID-OMR324>3.0.CO;2-H","article-title":"NMR relaxometric studies of Gd(III) complexes with heptadentate macrocyclic ligands","volume":"36","year":"1998","journal-title":"Magn Reson Chem"},{"key":"bib32-20250802","doi-asserted-by":"crossref","first-page":"7680","DOI":"10.1002\/chem.201200265","article-title":"Lower ligand denticity leading to improved thermodynamic and kinetic stability of the Gd3+ complex: the strange case of OBETA","volume":"18","year":"2012","journal-title":"Chemistry"},{"key":"bib33-20250802","article-title":"How the chemical properties of GBCAs influence their safety profiles in vivo","volume":"27","year":"2022","journal-title":"Molecules"},{"key":"bib34-20250802","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004424-200102000-00008","article-title":"Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment","volume":"36","year":"2001","journal-title":"Invest Radiol"},{"issue":"2\u20133","key":"bib35-20250802","first-page":"128","article-title":"Pharmacokinetics of gadomer-17, a new dendritic magnetic resonance contrast agent","volume":"12","year":"2001","journal-title":"MAGMA"},{"key":"bib36-20250802","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/RLI.0000000000000280","article-title":"Revisiting the pharmacokinetic profiles of gadolinium-based contrast agents: differences in long-term biodistribution and excretion","volume":"51","year":"2016","journal-title":"Invest Radiol"},{"issue":"1\u20132","key":"bib37-20250802","first-page":"308","article-title":"Tolerability of hypertonic injectables","volume":"490","year":"2015","journal-title":"Int J Pharm"},{"key":"bib38-20250802","article-title":"The dendritic cell response to classic, emerging, and homeostatic danger signals. Implications for autoimmunity","volume":"4","year":"2013","journal-title":"Front Immunol"},{"key":"bib39-20250802","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.xphs.2016.09.034","article-title":"If euhydric and isotonic do not work, what are acceptable pH and osmolality for parenteral drug dosage forms?","volume":"106","year":"2017","journal-title":"J Pharm Sci"},{"key":"bib40-20250802","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3174\/ajnr.A2640","article-title":"MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice","volume":"33","year":"2012","journal-title":"Am J Neuroradiol"},{"key":"bib41-20250802","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"bib42-20250802","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"bib43-20250802","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/neuonc\/noaa030","article-title":"Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases","volume":"22","year":"2020","journal-title":"Neuro Oncol"},{"key":"bib44-20250802","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jrr\/rrs053","article-title":"Usefulness of double dose contrast-enhanced magnetic resonance imaging for clear delineation of gross tumor volume in stereotactic radiotherapy treatment planning of metastatic brain tumors: a dose comparison study","volume":"54","year":"2013","journal-title":"J Radiat Res"},{"key":"bib45-20250802","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0730-725X(97)00015-5","article-title":"Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size","volume":"15","year":"1997","journal-title":"Magn Reson Imaging"},{"key":"bib46-20250802","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/jmri.1880020103","article-title":"High-dose gadoteridol in MR imaging of intracranial neoplasms","volume":"2","year":"1992","journal-title":"J Magn Reson Imaging"}],"container-title":["Investigative Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLI.0000000000000889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:09:19Z","timestamp":1754161759000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLI.0000000000000889"}},"subtitle":["A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent"],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rli.0000000000000889","relation":{},"ISSN":["1536-0210","0020-9996"],"issn-type":[{"value":"1536-0210","type":"electronic"},{"value":"0020-9996","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,13]]}}}